Hong Kong-listed AI drug discovery company Insilico Medicine and Eli Lilly sign a drug co-development deal worth up to $2.75B, with $115M in upfront payments

Eli Lilly just made a massive bet on AI-driven pharmaceuticals. The U.S. pharma heavyweight signed a co-development agreement with Hong Kong-listed Insilico Medicine, an AI drug discovery company. The deal is worth up to $2.75 billion.

Insilico pockets $115 million in upfront payments, with the remaining value tied to the partnership's progression. The collaboration focuses on bringing AI-developed drugs through the pipeline — a signal that Big Pharma is increasingly willing to write enormous checks for machine learning-driven discovery.

Insilico Medicine has built its reputation on using artificial intelligence to accelerate the notoriously slow and expensive drug development process. For Lilly, this deal represents a significant commitment to AI as a core tool in its R&D strategy.

The numbers speak for themselves. Up to $2.75 billion is serious money, even for a company Lilly's size.